166Tip Pembrolizumab Combined with Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma: Protocol for a Multi-Center, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002)
Hongjing Jiang,Xianwen Shang,Chao Zhang,Jie Yue,Xiaofeng Duan,Zhao Ma,Chong-An Chen,W. Zhang,Qingsong Pang,L. Liu,Xiubao Ren,Bin Meng,Gang Zhao,P. Zhang,Wei Yu,Yussanne Ma,L. Zhang,Y. Li
DOI: https://doi.org/10.1016/j.annonc.2021.10.185
IF: 51.769
2021-01-01
Annals of Oncology
Abstract:BackgroundEsophageal cancer (EC) is one of the most common cancers in the world. More than 50% of ECs occur in China, and more than 90% of them are esophageal squamous cell carcinoma (ESCC). The NCCN recommends neoadjuvant concurrent radiochemotherapy (neoCRT) followed by surgery for locally advanced ESCC. However, it will increase the complexity of the course, the difficulty of operation, and perioperative complications. Therefore, it is necessary to seek new strategies. A series of high-level evidence-based medical evidence has confirmed the good efficacy of pembrolizumab for advanced EC. To our best of knowledge, no randomized studies were conducted to compare the pembrolizumab combined with neoCT versus neoCRT in patients with locally advanced resectable ESCC to date.Trial DesignIn this trial, 342 patients (stage Ⅱ/Ⅲ) ESCC are enrolled. A central randomization system is used with an allocation ratio of 2:1. The experimental group (228 cases) will receive pembrolizumab (200mg IV D1 Q3W for 3 cycles), cisplatin (80mg/m2 IV D2 Q3W for 3 cycles) and paclitaxel (135mg/m2 IV D2 Q3W for 3 cycles), while the control group (114 cases) receive cisplatin (25mg/m2 IV D1 Q1W for 5 cycles), paclitaxel (50mg/m2 IV D1 Q1W for 5 cycles) combined with radiotherapy (41.4 Gy, 1.8Gy×23 times, 5 times per week for 5 weeks consecutively). Both groups will undergo McKeown surgery within 4-6 weeks after the end of neoadjuvant treatment. In addition, group A also receives pembrolizumab alone for one year as adjuvant therapy after surgery, or until the radiographically confirmed PD or other condition indicated for premature termination. The therapeutic session of the control lasts until post-surgery discharge (considering the long enrollment time, the postoperative treatment in the neoCRT group might be adjusted according to updated guidelines rather than observation only). Primary endpoints: event-free survival (EFS). Secondary endpoints: OS, DFS, ORR, R0 resection rate, and 30-day perioperative complications, Quality of life, and nutrition assessment.Clinical trial identificationNCT04807673.Legal entity responsible for the studyThe authors.FundingThis trial was partially funded by the Tianjin Science and Technology Committee Foundation (20JCZXJC00050) and the Beijing Xisike Clinical Oncology Research Foundation (No. Y-MSD2020-0346).DisclosureAll authors have declared no conflicts of interest. BackgroundEsophageal cancer (EC) is one of the most common cancers in the world. More than 50% of ECs occur in China, and more than 90% of them are esophageal squamous cell carcinoma (ESCC). The NCCN recommends neoadjuvant concurrent radiochemotherapy (neoCRT) followed by surgery for locally advanced ESCC. However, it will increase the complexity of the course, the difficulty of operation, and perioperative complications. Therefore, it is necessary to seek new strategies. A series of high-level evidence-based medical evidence has confirmed the good efficacy of pembrolizumab for advanced EC. To our best of knowledge, no randomized studies were conducted to compare the pembrolizumab combined with neoCT versus neoCRT in patients with locally advanced resectable ESCC to date. Esophageal cancer (EC) is one of the most common cancers in the world. More than 50% of ECs occur in China, and more than 90% of them are esophageal squamous cell carcinoma (ESCC). The NCCN recommends neoadjuvant concurrent radiochemotherapy (neoCRT) followed by surgery for locally advanced ESCC. However, it will increase the complexity of the course, the difficulty of operation, and perioperative complications. Therefore, it is necessary to seek new strategies. A series of high-level evidence-based medical evidence has confirmed the good efficacy of pembrolizumab for advanced EC. To our best of knowledge, no randomized studies were conducted to compare the pembrolizumab combined with neoCT versus neoCRT in patients with locally advanced resectable ESCC to date. Trial DesignIn this trial, 342 patients (stage Ⅱ/Ⅲ) ESCC are enrolled. A central randomization system is used with an allocation ratio of 2:1. The experimental group (228 cases) will receive pembrolizumab (200mg IV D1 Q3W for 3 cycles), cisplatin (80mg/m2 IV D2 Q3W for 3 cycles) and paclitaxel (135mg/m2 IV D2 Q3W for 3 cycles), while the control group (114 cases) receive cisplatin (25mg/m2 IV D1 Q1W for 5 cycles), paclitaxel (50mg/m2 IV D1 Q1W for 5 cycles) combined with radiotherapy (41.4 Gy, 1.8Gy×23 times, 5 times per week for 5 weeks consecutively). Both groups will undergo McKeown surgery within 4-6 weeks after the end of neoadjuvant treatment. In addition, group A also receives pembrolizumab alone for one year as adjuvant therapy after surgery, or until the radiographically confirmed PD or other condition indicated for premature termination. The therapeutic session of the control lasts until post-surgery discharge (considering the long enrollment time, the postoperative treatment in the neoCRT group might be adjusted according to updated guidelines rather than observation only). Primary endpoints: event-free survival (EFS). Secondary endpoints: OS, DFS, ORR, R0 resection rate, and 30-day perioperative complications, Quality of life, and nutrition assessment. In this trial, 342 patients (stage Ⅱ/Ⅲ) ESCC are enrolled. A central randomization system is used with an allocation ratio of 2:1. The experimental group (228 cases) will receive pembrolizumab (200mg IV D1 Q3W for 3 cycles), cisplatin (80mg/m2 IV D2 Q3W for 3 cycles) and paclitaxel (135mg/m2 IV D2 Q3W for 3 cycles), while the control group (114 cases) receive cisplatin (25mg/m2 IV D1 Q1W for 5 cycles), paclitaxel (50mg/m2 IV D1 Q1W for 5 cycles) combined with radiotherapy (41.4 Gy, 1.8Gy×23 times, 5 times per week for 5 weeks consecutively). Both groups will undergo McKeown surgery within 4-6 weeks after the end of neoadjuvant treatment. In addition, group A also receives pembrolizumab alone for one year as adjuvant therapy after surgery, or until the radiographically confirmed PD or other condition indicated for premature termination. The therapeutic session of the control lasts until post-surgery discharge (considering the long enrollment time, the postoperative treatment in the neoCRT group might be adjusted according to updated guidelines rather than observation only). Primary endpoints: event-free survival (EFS). Secondary endpoints: OS, DFS, ORR, R0 resection rate, and 30-day perioperative complications, Quality of life, and nutrition assessment. Clinical trial identificationNCT04807673. NCT04807673. Legal entity responsible for the studyThe authors. The authors. FundingThis trial was partially funded by the Tianjin Science and Technology Committee Foundation (20JCZXJC00050) and the Beijing Xisike Clinical Oncology Research Foundation (No. Y-MSD2020-0346). This trial was partially funded by the Tianjin Science and Technology Committee Foundation (20JCZXJC00050) and the Beijing Xisike Clinical Oncology Research Foundation (No. Y-MSD2020-0346).